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Renal urate excretion in patients with Wilson's disease. Because
many patients with Wilson's disease have hypouricemia, a study
was made of 10 patients and 10 control persons to determine the
nature of the renal excretory defect. Uric acid excretion was
studied before and after the administration of pyrazinamidem—an
agent which is postulated to selectively block urate secretion.
Urate excretion was also correlated with the quantity of various
types of amino acids excreted. In the presence of pyrazinamide,
total urate excretion is decreased markedly just as in normal
individuals. It appears that proximal reabsorption of urate may
not be impaired. There is a positive correlation between ex-
cessive urate excretion and that of serine, arginine, valine, and
glutamine.
Excretion rénale des urates chez les malades atteints de maladie
de Wilson. Du fait que beaucoup de malades atteints de maladie
de Wilson ont une hypouricémie une étude a été réalisée chez
dix malades et dix sujets témoins afin de determiner Ia nature
du trouble de l'excrétion des urates. L'excrétion d'acide urique
a été étudiCe avant et aprés l'administration de pyrazinamide,
agent dont on suppose qu'il bloque électivement Ia secretion
d'urate. L'excrCtion d'urate a été aussi corrélée avec Ia quantité
de divers acides aminés excrétés. En presence de pyrazinamide
l'excrétion totale d'urate est notablement diminuée, comme chez
les témoins. II apparait que Ia reabsorption proximale des urates
n'est probablement pas diminuée. II existe une correlation posi-
tive entre l'excrCtion excessive d'urate et l'excrétion de sérine,
d'arginine, de valine et de glutamine.
Renal urate excretion is increased in Wilson's disease.
Most patients with untreated Wilson's disease have hypo-
uricemia, and the clearance of urate is from 20 to 30 mI/mm,
which is two to three times normal [1—3]. Urate turnover
and metabolism have been examined in these patients, and
14C uric acid injection studies have revealed that the urate
pooi size is markedly diminished [4, 5]. This has led to the
conclusion that the hypouricemia in these patients is
secondary to a renal lesion which causes renal urate
wasting.
The nature of the renal lesion responsible for urate
wasting has been difficult to establish because there is no
adequate animal model for studying the problem. Renal
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urate excretion is thought to involve filtration, reabsorp-
tion, and secretion from the tubule [6]. Consequently, direct
analysis of urine urate excretion sheds little light on whether
the hypouricemia is due to decreased reabsorption or to an
increased rate of urate secretion.
Recently, studies of urate excretion using the antituber-
culosis drug pyrazinamide have been used in an attempt
to clarify the mechanisms for urate transport under various
conditions. In man, the administration of pyrazinamide
depresses urate excretion by 95% [7]. Stop-flow experi-
ments have revealed that pyrazinamide inhibits the secre-
tory peak in mongrel dogs while leaving the reabsorption
dip unaffected [8]. In Dalmatian dogs, where there is little
reabsorption of urate, pyrazinamide blocks urate excre-
tion [9]. This has led to the concept that pyrazinamide
selectively blocks secretion of uric acid at a site distal to
the reabsorptive site. Urate excretion has been character-
ized in normal man [10] and in patients with renal im-
pairment [11], with gout [12], and under the influence of
chlorothiazide diuretics [13], using pyrazinamide as a tool.
Recent studies, however, have shown that the action of
pyrazinamide on tubular transport may affect both reab-
sorption and secretion rates in a dose-related way so that
any analysis of pyrazinamide-induced changes of urate
excretion will be influenced by a complete understanding
of the segmental site of net secretory or reabsorptive pro-
cesses along the nephrori.
We have examined urate filtration, reabsorption, and
secretion using pyrazinamide in ten patients with Wilson's
disease in an attempt to determine whether these patients
have defective reabsorption.
Methods
Ten patients with Wilson's disease were tested in the
Renal Function Laboratory. All ten patients had Wilson's
disease diagnosed on the basis of decreased serum cerulo-
plasmin concentration or the findings of copper turnover
studies, which showed failure of intravenously injected
copper tagged with radioactive carbon to incorporate with
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serum ceruloplasmin, or increased urinary copper excretion
(greater than 100 J.Lg/24 hr), or both. In addition, Kayser-
Fleischer rings were seen either with the naked eye or on
slit-lamp examination. Eight patients had been treated with
penicillamine from 2.5 to 13 years. All of these eight
patients had been off penicillamine therapy for at least
2 weeks (usually 4 weeks) before the renal studies. Two
patients were studied before penicillamine therapy was
given. These latter two patients did not have any clinical
evidence of hepatic, neurologic or renal disease but were
discovered during the screening of family members of
affected patients. All 10 patients had a glomerular filtra-
tion rate (GFR) greater than 50 mI/mm.
Patients came to the Renal Function Laboratory in a
hydrated but fasting state. Standard inulin clearance deter-
minations were performed. A bladder catheter was in-
serted, and the bladder was twice-rinsed with saline solution
and air at the end of each clearance period. Plasma samples
were obtained at the beginning and end of each period.
If plasma concentrations of inulin or urate changed, the
plasma concentration was extrapolated to a point 5 min-
utes before the midpoint of each period. After four ade-
quate 20-minute periods, the patient was given 3.0 g of
pyrazinamide as crushed tablets orally. Subsequently, two
30-minute periods and then 15- to 20-minute clearance
periods were obtained for at least another 2 hours. Plasma
and urine uric acid concentrations for the current studies
were measured by the uricase method [14]. Measurements
of uric acid concentration prior to 1963 were performed by
a different method. Inulin clearance was determined by
a modification of the Roe Autoanalyzer technique [15],
and blood pressure was monitored at 30-minute intervals
throughout the test.
The rate of secreted urate (Ts urate) was calculated as
the amount of urate excreted per ml GFR before the drug
was given minus the amount excreted per ml GFR after
the drug was given at the point where the maximal sup-
pression of urate secretion was evident (Table 1):
Uv Uv
Ts urate = urate (control) — urate (drug),
''tn
where C1, is the clearance of inulin and UVurate is the
urinary excretion of urate.
The tubular reabsorption (Tr) of urate was expressed as
a percentage of the filtered load. This was calculated in
the period of the lowest UVurate per nephron after pyra-
zinamide was given:
C x plasma urate — UVTr urate= In ura C x 100.C1, x plasma urate
Fractional urate excretion (FE) was expressed as the per-
centage of the filtered urate that was excreted during the
administration of pyrazinamide:
FE — urate x 100U rate — c1,x plasma urate
Table 1. Representative study of one patient
with Wilson's disease a
C1, Urate, mg/mi Car,
Time mi/mm Urine Plasma mi/mm
UV urate/
10:15—10:37 100 0.78 0.064
10:37—10:58 89 0.74 0.064 15.5 8.79
10:58—11:17 152 0.63 0.064 (mean) (mean)
Pyrazinamide given at 11:25 (3.0 g)
11:17—11:39 71 0.74 0.059 16.4 13.6
11:39—12:00 114 0.17 0.059 14.1 7.3
12:00—12:40 98 0.089 0.057 7.0 4.1
12:40—1:05 99 0.060 0.056 4.1 2.3
1:05—1:28 99 0.046 0.056 2.8 1.6
1:28—1:56 99 0.027 0.056 1.9 1.1
1:56—2:22 96 0.029 0.056 1.6 0.95
2:22—2:50 100 0.047 0.056 3.9 2.2
Ts urate = 8.79—0.95 = 7.84iig/ml GFR
Trurate =56—0.95/56x 100=98.30%
FE urate = (0.95/56)x 100 = l.70°/o
a = clearance of inulin; Cur =clearance of urate; UV
urate = urate excretion; Ts urate secretion rate of urate;
Tr urate = rate of tubular reabsorption of urate; FE urate =
fractional excretion rate of urate; and GFR =glomerular
filtration rate.
Data on amino acid excretion were collected within
3 months of the study of urate excretion, while patients
were off penicillamine therapy. Amino acids were meas-
ured on an amino acid analyser (Phoenix).
Results
All but two patients (6 and 9) had been on penicillamine
therapy for several years; one patient was treated for
13 years (Table 2). In the eight treated patients, the serum
uric acid concentration had been low, and in all but one
Table 2. Patients with Wilson's disease
Patient Plasma urate,
mg/100 ml
Initial Present
C1,, ,a
mi/mmn/1.73 m2
Treatment,
years
1 1.3 3.0 65 12
2 1.3 4.2 100 12
3 1.7 4.0 51 13
4 2.4 5.3 91 2.5
5 3.4 5.2 107 2.5
6 5.0 3.8 63 0
7 1.0 5.4 95 4
8 1.9 5.1 99 7
9 4.8 4.8 133 0
10 2.5 5.6 113 3
Mean 2.33 4.65 91.7 5.6
a = clearance of inulin.
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Table 3. Clearance data on 10 patients with Wilson's disease and on 10 control subjects a
Patients C1,,
mi/min/l.73 m2
"urate'
mg/loom!
UV urate
(baseline),
4ag/min/ml GFR
Curate/C In Ts urate,
fig/mi GFR/mg
FE urate,
%
Secreted urate/
excreted urate,
%
1 65 3.0 5.7 0.20 1.40 1.7 73.7
2 100 4.2 8.6 0.17 1.85 1.6 90.6
3 51 4.0 7.5 0.39 1.24 2.5 66.5
4 91 5.3 16.7 0.20 2.92 8.1 92.8
5 107 5.2 9.4 0.16 1.72 3.6 94.3
6 63 3.8 6.1 0.26 1.42 1.5 88.5
7 95 5.4 12.3 0.09 2.22 2.4 97.5
8 99 5.1 5.4 0.13 0.83 1.4 78.4
9 133 4.8 6.9 0.11 1.08 2.3 75.3
10 113 5.6 8.4 0.13 1.24 2.0 82.2
Mean±sD 91.7±25.2 4.64±0.85 8.7±3.5 0.188±0.086 1.59±0.61 2.71±2.0 84.0±10.3
Control
1 117 5.6 7.1 0.11 0.93 2.6 72.9
2 97 6.4 5.5 0.09 0.77 1.2 89.6
3 108 6.1 5.5 0.08 0.67 1.8 74.4
4 107 4.8 5.5 0.08 0.75 0.6 65.6
5 106 4.8 3.8 0.06 0.52 1.3 66.1
6 110 5.9 4.9 0.07 0.63 0.9 75.8
7 101 4.3 7.6 0.16 1.42 2.7 80.0
8 114 3.8 3.4 0,14 0.76 6.6 83.7
9 119 5.8 5.3 0.08 0.74 1.4 81.4
10 113 5.8 3.2 0.07 0.46 2.6 83.9
Mean±sD 109.0±6.9 5.33±0.85 5.5±1.4 0.098±0.034 0.765±0.27 2.17±1.7 77.3±7.8
a P1 = plasma urate concentration. See Table I for remaining abbreviations.
(patient 1), after treatment the concentration had increased
to normal. Neither of the two untreated patients had an
abnormal concentration of serum uric acid, although
when the clearance studies were done, one had a low-
normal level. This patient (6) had an abnormally high
clearance of urate, whereas the other (patient 9) had a
clearance within normal limits (Table 3) when ex-
pressed as a percentage of C1. None of the patients had
an inulin clearance below 50 mI/mm, and most were well
within the normal range (Table 3). However, C1 was
significantly lower in patients with Wilson's disease than
in control subjects. Cur/Cm for our patients was 0.188,
which was significantly higher than the 0.098 for the con-
trol population (P<O.O1). The filtered urate load in the
patients with Wilson's disease was somewhat higher per
nephron, reflecting the slightly higher levels of plasma
urate in this group of patients. The fractional excretion of
urate reflects the filtered urate that escapes reabsorption
and is 2.71 % in the patients with Wilson's disease. This
value is not significantly different from that of 2.17% in
the control patients. This lack of difference is not related
to a difference in filtered urate because there is no apparent
change in the FE of either group as the rate of filtered
urate changes. The Tr urate was 97.2% of the filtered load,
which was not significantly different from the 97.8% re-
absorbed by the controls. There was no difference noted
in the reabsorption of urate at any filtered load.
In Fig. 1, the Ts urate was correlated to plasma urate
concentration. It has been shown that Ts urate increases
with an increase in the concentration of plasma urate or
filtered urate, which is reflected in the solid line as plotted
from Steele and Rieselbach's data [10] and can be seen in
our normal control subjects. Most patients with Wilson's
disease had plasma urate concentrations in the range of the
controls, but the patients with Wilson's disease had higher
Ts urate values than did the controls. Because only a minor
error results if a linear correlation of Ts urate with plasma
urate is assumed in controls, we corrected Ts urate for
plasma urate (Table 3) in order to compare them with the
patients who had Wilson's disease. Ts urate was signif i-
cantly higher (P<0.005) in the patients with Wilson's
disease. It was also significantly higher if this correction
was not made and Ts was compared directly (P<0.001).
Note that one of the patients off penicillamine therapy
(patient 6, Table 3) had a high Ts urate in the same range
as those who were receiving penicillamine. Because the
GFR is higher in control subjects, Ts was plotted against
GFR, but there was no change in Ts urate in either group
as GFR changed. Steele and Rieselbach [11] have shown
that Ts urate per nephron does not change until the GFR
approaches 15 mI/mm.
Amino acid excretion was studied in these patients
within 3 months of the time the urate excretion studies
were performed (Table 4). Again the Ts urate values in
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Fig. 1. Urate secretion in normal persons and in patients with
Wilson's disease in the presence of pyrazinamide. Solid line taken
from data by Steele and Rieselbach [101. Ts urate= secretion
rate of urate; plasma urate = plasma urate concentration; and
GFR = glomerular filtration rate.
Table 4 have been corrected for the level of plasma urate.
There was a generalized aminoaciduria in several of the
patients. An attempt was made to relate the increased
amino acid excretion to the increase in Ts urate. Serine
excretion was positively correlated with Ts urate (r =0.63,
P <0.05). There was also a positive correlation of Ts urate
with arginine, valine, and glutamine (Table 4). Increased
glycine excretion was not significantly correlated with in-
creased Ts urate (r=O.31).
Discussion
In one study of Wilson's disease, untreated patients had
a mean CLj of 23.9 (16 to 30) ml/min, a mean C1, of
97.3 (56 to 140) mI/mm and a C/C1,, of 0.245 [2]. The
serum uric acid concentrations in our patients improved
virtually to normal on long-term penicillamine treatment,
and their urate clearance values were lower, averaging
15.6 mI/mm. However, they were clearing more urate than
the normal subjects in our study or those reported by
Steele and Rieselbach [10].
Uric acid clearance has been consistently high in patients
with Wilson's disease even though some patients have total
excretion values in the normal range. Sorensen and Kap-
pas [5] have shown that the urate pool in these patients is
small and that the metabolic turnover rate is normal. Their
data, as well as those of Leu and associates [2], suggest
that urate clearance returns toward normal after treatment
with penicillamine. Several of our patients had been treated
for more than 10 years. Urate clearance was still high in
these patients, suggesting a continuing abnormality of
urate excretion by the kidney in some patients.
The use of pyrazinamide to delineate the mechanism of
urate excretion in Wilson's disease is limited because of the
Table 4. Amino acid excretion a in patients with Wilson's diseasea
Pa-
tient
Glycine Aspar-
tic
acid
Leucine Serine Orni-
thine
Gluta-
mine
Lysine Cystine Argi-
nine
Alanine Valine Phenyl-
alanine
Tyro-
sine
Ts urate
per mg
ofplasma
urate,
.tg/mI
GFR/mg
1 5,768 9.2 85 870 145 — 642 2,291 101 713 71 127 297 1.42
2 4,460 34 52 1,072 242 52 172 80 48 324 TR 96 184 1.85
3 2,543 71 TR 444 — 77 364 170 72 348 40 334 136 1.24
4 6,225 123 150 2,284 229 264 1,364 314 197 1,254 127 109 220 1.72
5 6,478 67 100 1,324 80 91 352 224 52 751 39 123 232 1.40
6 8,888 76 89 1,515 161 72 1,017 116 49 1,640 70 182 283 1.08
7 704 TR 61 202 27 18 80 31 37 175 29 23 48 2.92
8 1,060 82 48 358 16 48 517 60 49 237 36 156 94 0.83
9 2,009 77 61 680 — 104 245 175 37 391 60 224 257 1.24
10 1,749 4.0 107 246 186 26 56 80 62 260 37 105 125 2.22
Nor- <4,565 12—I 13 33—73 264—573 7—38 25—84 700 40—228 44—82 852 163 76—399 45—280
ma!
r 0.31 0.41 0.58 0.63c 0.37 0.61° 0.42 0.02 0.65° 0.34 0.61° 0.52 0.00
a jimoles/24 hr.
e Significant (P< 0.05) (Ts urate compared with amino acid excretion).
12 0
0
8
0
0
0
6 0
0 00 S
4
2
0 2 4 6
Plasma urate, mg/100 ml
Urate excretion with Wilson's disease 335
controversy surrounding the effect of pyrazinamide itself
on tubular function. Precise interpretation depends on a
selective and complete blockage of secretion at a site distal
to any reabsorptive site. There are serious questions about
whether pyrazinamide may block reabsorption as well as
secretion. Weiner and Tinker [161 have reviewed this prob-
lem and have shown that net secretion is blocked, but they
also have shown that pyrazinamide is transported bidirec-
tionally in different species. Although they showed that
net reabsorption may be blocked only by extremely high
doses, the possibility exists that the doses used in this
study could have affected both reabsorption and secretion.
A recent editorial has outlined the growing body of
literature concerning the action and site of action of
pyrazinamide [17], concluding that it is not possible at the
present time to state with absolute certainty that the effect
of pyrazinamide is a total and selective inhibition of uric
acid secretion.
The validity of assuming that Ts urate as described herein
measures the rate of secretion of urate quantitatively de-
pends upon any secretory site being distal to the reabsorp-
tive site(s). Any large area of overlap or the presence of a
distal reabsorptive site makes it difficult to interpret urate
excretion as being just a function of secretion, inasmuch as
secreted urate may be normally reabsorbed distally. There
is clear evidence of distal tubular secretion in several
animals [7]. There is reasonably valid evidence that secre-
tion, as well as the reabsorption of urate, may occur in the
proximal tubule [16]. At this time, there is some evidence
of distal tubular reabsorption in the rat [18] and possibly
in man [19, 20]. Consequently, the analysis of pyrazin-
amide-induced changes of urate excretion will be influenced
by a final and complete understanding of the sequential
site of secretory or reabsorptive activity along the nephron.
Nevertheless, a few comments and speculations may be in
order.
Pyrazinamide, apparently, has as much effect on de-
creasing net urate transport in Wilson's disease as in nor-
mal subjects. Copper toxicity could prevent the effect of
pyrazinamide on either reabsorption or excretion, but an
impairment of the effect of pyrazinamide by copper should
result in a higher excretion of urinary urate than expected
after pyrazinamide administration and it should cause an
apparent decrease in the amount of reabsorbed urate,
which we did not see. A major overlap of reabsorptive and
secretory sites or a significant distal reabsorptive site would
make quantitative analysis of our data difficult, but on
the assumption that pyrazinamide blocks secretion and
does not alter reabsorption, the lack of an alteration in the
fractional excretion of urate, while secretion is blocked,
would be inconsistent with the suggestion that excess ex-
cretion in our patients is due to a defect in proximal reab-
sorption.
The presence of a distal reabsorptive site with a de-
creased capacity in Wilson's disease is an alternative inter-
pretation to that of an apparent increase in urate secretion.
Our results are also consistent with the presence of such a de-
fect in a distalmost reabsorptive site in association with an in-
creased Ts urate at a more proximal or even somewhat over-
lapping site. However, assuming that the drug blocks secretion
only, it would be likely that the FE of urate would be increased
in the presence of pyrazinamide if there was a significant
depression in the distal reabsorption of urate, unless the
distal reabsorptive component is large and pyrazinamide
reduces the load presented to such a site within the reduced
limits of its reabsorptive capacity. This model for urate
transport has been proposed [20].
Sorensen and Kappas [5] and Beam and associates [21]
have also suggested, on the basis of increased urate clear-
ances, that net renal urate reabsorption was impaired in
patients with Wilson's disease. They gave probenecid to a
patient who had Wilson's disease, and they presumed that
the reduced uricosuric effect was evidence for a defect in
reabsorption. They cited, as evidence, a patient with the
Fanconi syndrome in whom the same result was obtained.
There are other possible explanations for urate wasting
in Wilson's disease and the action of pyrazinamide. Blue-
stone et al [22] have shown that plasma proteins are capable
of binding urate. It may be that urate binding is decreased
in Wilson's disease and increased by pyrazinamide ad-
ministration, but this is purely speculation and our data
do not bear on this point.
One problem in our study concerns the effect of peni-
cillamine administration on either renal function or the
action of pyrazinamide. Penicillamine may alter the rate of
reabsorption or secretion selectively, leaving alterations in
only one part of the transport mechanism. However, two
patients had not taken penicillamine, and one of these had
a definite elevation in urate secretion and no apparent
abnormality in reabsorption just like the patients who
received the drug. The other patient had no significant
alteration in the rate of excretion, reabsorption, or secre-
tion. Sorensen and Kappas [5] treated normal persons with
penicillamine and found no alteration in urate clearance,
suggesting that neither the secretion nor reabsorption of
urate was altered.
There is a positive correlation between Ts urate and the
quantitative excretion of some of the amino acids. It seems
probable that the copper toxicity is affecting amino acid
transport and urate transport independently. However, sev-
eral studies have suggested that alterations in amino acid ex-
cretion may influence uric acid excretion [7, 23—25]. Yü,
Berger and Gutman [7] have shown that glycine loading
produces uricosuria. In our study, there was no significant
correlation between the rates of glycine excretion and
amino acid excretion; however, glycine loading caused excess
serine excretion, and serine excretion correlated positively
with amino acid excretion in both our study and that of
YU et al [7]. Furthermore, gouty patients with a relative
decrease in Ts urate have a decrease in the renal excretion
of several amino acids [12, 26]. Aminoaciduria and hypo-
uricemia are closely linked in Wilson's disease [27—29], and
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there are abundant references to other conditions in which
aminoaciduria and hypouricemia are linked, such as
patients with primary hyperglycinuria [30—32], Fanconi's
syndrome [33] or lung carcinoma [34]. It may be that
amino acids have a causal role, and affect urate excretion,
or vice versa. If there is a distal reabsorptive defect for
urate masked by pyrazinamide administration, it could be
coupled with amino acid reabsorption in some way.
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